Physician
Oncology
Dr. Alessandra Ferrajoli, MD
|
|
Give Review
Alessandra Ferrajoli is an expert in the field of Oncology. Alessandra Ferrajoli is a published doctor and has 51 publications published. The lastest was: 'Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.' Alessandra Ferrajoli, MD accepts all Medicare patients.
Publications
- Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal ...
- Outcomes for patients with chronic lymphocytic leukemia and Acute leukemia or myelodysplastic syndrome.
- A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic Leukemia.
- Incidence and Prognostic Impact of Other Cancers in a Population of Long-Term Survivors of Chronic Lymphocytic Leukemia.
- Richter Syndrome in Chronic Lymphocytic Leukemia.
- β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with Chronic lymphocytic...
- Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with Acute lymphoblastic leukaemia.
- Estimated glomerular filtration rate changes in patients with chronic myeloid Leukemia treated with tyrosine kinase inhibitors.
- Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic Leukemia.
- Outcomes of patients with chronic lymphocytic Leukemia after discontinuing ibrutinib.
- Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.
- Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed Acute myeloid leukemia.
- High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic Leukemia is an independent predictor of adverse outcome.
- Second Cancers and Richter Transformation Are the Leading Causes of Death in Patients With Trisomy 12 Chronic Lymphocytic Leukemia.
- Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with Chronic lymphocytic leukae...
- SnapShot: Chronic Lymphocytic Leukemia.
- Incidence of secondary neoplasms in patients with Acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid p...
- A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic Leukemia.
- Life After FCR: Outcomes of patients with chronic lymphocytic Leukemia who progress after frontline treatment with Fludarabine, Cyclophosphamide and Rituximab.
- Clinical characteristics and outcomes in patients with Acute promyelocytic leukaemia and hyperleucocytosis.
- Safety and activity of ibrutinib plus rituximab for patients with high-risk Chronic lymphocytic leukaemia: a single-arm, phase 2 study.
- Utility of Quantitative Flow Cytometry Immunophenotypic Analysis of CD5 Expression in Small B-Cell Neoplasms.
- Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with Acute lymphoblastic leukemia (ALL).
- FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic Leukemia.
- STAT3-Activated GM-CSFRalpha Translocates to the Nucleus and Protects CLL Cells from Apoptosis.
- Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic Leukemia cells.
- Eradication of bone marrow minimal residual disease with first-line chemoimmunotherapy may prompt early treatment discontinuation in chronic lymphocytic Leukemia.
- Correlation between FDG/PET findings, histological features, clinical characteristics and survival in 332 patients with chronic lymphocytic Leukemia.
- CD49d Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia.
- Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
- Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic Leukemia: Joint experience of the MD Anders...
- Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic Leukemia: Analysis of persistent and new-onset cytop...
- Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic Leukemia.
- Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic Leukemia.
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed Acute myeloid leukemia (AML).
- A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of Myelodysplastic syndrome.
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia.
- Pleural effusions in patients with Acute leukemia and myelodysplastic syndrome.
- Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia: A Comparison of CLL and HapMap Genot...
- The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic Leukemia.
- Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic Leukemia B-cell activation and migration.
- Interfering with CD40 ligation: a sensitive matter in chronic lymphocytic Leukemia.
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm Acute myeloid leukemia.
- Characteristics associated with important clinical end points in patients with chronic lymphocytic Leukemia at initial treatment.
- Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic Leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR...
- Treatment of B-cell chronic lymphocytic Leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.
- Effective treatment of Acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
- Clofarabine combinations as Acute myeloid leukemia salvage therapy.
- Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting ...
- Autoimmune cytopenias in patients with chronic lymphocytic Leukemia treated with ibrutinib.
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
University of Perugia Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1952497687 | |
| NPPES Provider LastName | FERRAJOLI | |
| NPPES Provider FirstName | ALESSANDRA | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 446.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 19.0 | |
| Percent Opioid Claims | 4.26 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1952497687 |
| Last Name Of The Provider | FERRAJOLI |
| First Name Of The Provider | ALESSANDRA |
| View All |
Similar Doctors
|
|
Dr. Lori A. Leslie, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard P. Baltz, MD |
|
|
Dr. Mariana Chavez MacGregor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth J. Shpall, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Robert C. Bast Jr., MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Padmanee Sharma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edmund S. Kopetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John O. Mendelsohn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bryan K. Kee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rashmi K. Murthy, MD |
|
|
Dr. Leonard A. Zwelling, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jorge E. Romaguera, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Nicholas E. Papadopoulos, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Paulo M. Hoff, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Abdul-Masih F P. Farha, MD |
|
|
Dr. Henry I. Zaleski Jr., MD
This Doctor is OpenDoctor Recommended.
|